Atypical Antipsychotic class drugs

11 results

  • Abilify

    (ARIPIPRAZOLE)
    Otsuka America Pharmaceutical, Inc.
    Usage: ABILIFY (aripiprazole) is indicated for the treatment of schizophrenia, acute manic and mixed episodes associated with Bipolar I Disorder, adjunctive treatment of major depressive disorder, irritability associated with autistic disorder, and treatment of Tourette's disorder.

  • Abilify asimtufii

    (Aripiprazole)
    Otsuka America Pharmaceutical, Inc
    Usage: ABILIFY ASIMTUFII is indicated for the treatment of schizophrenia in adults and for maintenance monotherapy of bipolar I disorder in adults.

  • Abilify maintena

    (aripiprazole)
    Otsuka America Pharmaceutical, Inc.
    Usage: ABILIFY MAINTENA (aripiprazole) is indicated for the treatment of schizophrenia and as maintenance monotherapy for bipolar I disorder in adults.

  • Abilify mycite

    (ARIPIPRAZOLE)
    Otsuka America Pharmaceutical, Inc.
    Usage: ABILIFY MYCITE is indicated for treating adults with schizophrenia, bipolar I disorder (including both acute and maintenance phases), and as adjunctive therapy for Major Depressive Disorder. It features an Ingestible Event Marker (IEM) sensor to track medication ingestion.

  • Caplyta

    (lumateperone)
    Intra-Cellular Therapies, Inc
    Usage: CAPLYTA is indicated for treating schizophrenia in adults and for depressive episodes associated with bipolar I or II disorder in adults, both as monotherapy and as adjunctive therapy with lithium or valproate.

  • Fanapt

    (iloperidone)
    Vanda Pharmaceuticals Inc.
    Usage: FANAPT® is indicated for the treatment of schizophrenia in adults and for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.

  • Geodon

    (ziprasidone hydrochloride)
    ROERIG
    Usage: GEODON is indicated for treating schizophrenia, acute manic or mixed episodes of bipolar I disorder (both as monotherapy and adjunct to lithium or valproate), and for acute agitation in schizophrenic adults needing rapid control. Caution is advised due to potential QT/QTc interval prolongation risks.

  • Invega sustenna

    (paliperidone palmitate)
    Janssen Pharmaceuticals, Inc.
    Usage: INVEGA SUSTENNA (paliperidone palmitate) is indicated for the treatment of schizophrenia and schizoaffective disorder in adults, both as monotherapy and as an adjunct to mood stabilizers or antidepressants.

  • Lybalvi

    (olanzapine and samidorphan L-malate)
    Alkermes, Inc.
    Usage: LYBALVI is indicated for the treatment of schizophrenia in adults and for Bipolar I disorder in adults, including acute treatment of manic or mixed episodes (as monotherapy or adjunct to lithium/valproate) and maintenance monotherapy.

  • Nuplazid

    (pimavanserin tartrate)
    Acadia Pharmaceuticals Inc.
    Usage: NUPLAZID® is indicated for treating hallucinations and delusions associated with Parkinson's disease psychosis.